Strides Pharma Science Limited (STAR) fair value: what the stock is really worth
We calculate from audited financials what Strides Pharma Science Limited is really worth. The fair value tells you whether the price is too high or too low, the quality score (0 to 100) how solid the business behind it is. 26 models, 37 quality factors, updated daily.
Watch Strides Pharma Science Limited for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for free
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 13, 2026.
How to read this chart
60‑month range ₹263.82 – ₹1,636 · fair‑value band ₹427.61 – ₹1,499 · the ₹1,183 price screens above the ₹912.24 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 2 fiscal years are left out: there the valuation rested on only a fraction of the usual models. Dashed = 300-day average. As of Sep 13, 2026.
Strides Pharma Science Limited develops, manufactures, and sells pharmaceutical products in Africa, Australia, North America, Europe, Asia, and internationally. The company offers pharma generics in various forms, such as tablets, hard and soft gelatin capsules, sachets, and liquids, as well as nasal spray, gels, powders, solids, ointments, and creams.
Show more
Strides Pharma Science Limited develops, manufactures, and sells pharmaceutical products in Africa, Australia, North America, Europe, Asia, and internationally. The company offers pharma generics in various forms, such as tablets, hard and soft gelatin capsules, sachets, and liquids, as well as nasal spray, gels, powders, solids, ointments, and creams. It also develops branded generics products for the treatment of chronic therapies, including women's health, central nervous system, cardiovascular, diabetes, dermatology, and probiotics under the Renerve, Unibrol, Combiart, Duotab, and Vitafer brands; and anti-retroviral, anti-malarial, anti-tuberculosis, Hepatitis, and other infectious disease drug segments for institutional business. The company was formerly known as Strides Shasun Limited and changed its name to Strides Pharma Science Limited in July 2018. The company was incorporated in 1990 and is based in Bengaluru, India.
Stock analysis
Strides Pharma Science Limited (STAR) currently trades at ₹1,183, while our model-based Fair Value estimate is ₹912.24, implying the stock looks roughly 29.7% overvalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of ₹1,120 per share, and 6 of the 26 models we run sit above the ₹1,183 price.
Bear case: the Asset-Based group reads lowest at ₹225.89, and 20 of the 26 models stay below the price. Evidence for this calculation is high.
Scenario range: ₹427.61 (bear) to ₹1,499 (bull), the price of ₹1,183 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 56/100 (solid quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Strides Pharma Science Limited reported revenue of ₹48.6B in FY2026 versus ₹30.6B in FY2022, a compound +12.3%/yr. Reported net income was ₹5.6B in FY2026.
Key figures
Market cap ₹109B (≈ $1.1B) · P/E ratio 19.6 · P/S ratio 2.24 · EPS (TTM) ₹60.39 · Dividend yield 0.4% · Net margin 11.4% · Return on equity 20.0% · Return on assets (EBIT) 4.5%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 38 out of 100 (low confidence).
What moves the price
The share trades about 4% below its 52-week high and 54% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −17% fair-value upside, at −23%, STAR screens richer than that median.
Fair Value models
Bear ₹427.61Fair Value ₹912.24Bull ₹1,499
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2026 figures (about 5 months old). Earnings retained since then (₹25.34 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.62/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+8.6%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+9.8%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+8.2%
Revenue growth 21 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+13.2%
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
’26
What shareholders gained per year (last 5 years), in INR ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in INR: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+31.6%
Earnings growth per share plus dividend.
Earnings per share, growth per year+31.2%
Dividend (yield on the price)0.4%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.31% vs 18%, picking up
Profit margin 2021 to 2026 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.10% → 15%
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+49.5%
Yearly growth needed for the next five years to justify today's price.
Compare Strides Pharma Science Limited with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 612 stocks
Beats the industry median on 9/14 measures
Overall it ranks above its industry peers.
Valuation
Quality Score56 · Above median
Fair Value upside−14% · Below median
Profitability
Return on equity (TTM)20% · Top 25%
Return on assets7% · Top 25%
Net margin (TTM)11% · Above median
Operating margin (TTM)14% · Above median
Growth and dividend
Revenue growth11% · Above median
Dividend yield (TTM)0.4% · Bottom 25%
Balance sheet
Debt / equity0.18× · Above median
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Strides Pharma Science Limited (STAR) overvalued or undervalued?
As of Sep 13, 2026, our model estimates a fair value of ₹912.24 versus a price of ₹1,183, about −23% upside (overvalued).
What is the fair value of STAR?
Our model-based fair value for Strides Pharma Science Limited is ₹912.24 (as of Sep 13, 2026), built from audited fundamentals. The current price: ₹1,183.
What is the quality score of STAR?
Strides Pharma Science Limited has a Quality Score of 56/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Strides Pharma Science Limited (STAR)?
Our model-based price target is the fair value of ₹912.24 (as of Sep 13, 2026) from 26 valuation models. Cautious scenario ₹427.61, optimistic scenario ₹1,499. It is a calculation from audited fundamentals, not an analyst target.
What is the Strides Pharma Science Limited stock forecast for 2026?
Our models put fair value at ₹912.24, about −23% upside versus a price of ₹1,183 (overvalued). Cautious scenario ₹427.61, optimistic scenario ₹1,499. The calculation is refreshed regularly with new filings.
What is the revenue of Strides Pharma Science Limited (STAR)?
Strides Pharma Science Limited reported trailing-twelve-month revenue of about ₹48.6B (latest available figure, as of Sep 13, 2026).
Does Strides Pharma Science Limited pay a dividend?
Strides Pharma Science Limited currently shows a dividend yield of about 0.42% relative to its recent price (as of Sep 13, 2026).
What growth is priced into Strides Pharma Science Limited (STAR)?
For today's price to be fair in a discounted-cash-flow model, Strides Pharma Science Limited would have to grow free cash flow by +49.5 % per year for five years (discount rate 12.4 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +8.2 % per year. As of Sep 13, 2026.
What discount rate (WACC) does the fair value of STAR use?
Our models discount Strides Pharma Science Limited at 12.4 %: a base by market capitalisation (small), damped by beta 0.34, country premium for India. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Strides Pharma Science Limited that is +49.5 % per year a year over ten years, using the same discount rate (12.4 %) and the same formula as our fair value.
How much growth has Strides Pharma Science Limited (STAR) delivered so far?
Over the past 5 years revenue at Strides Pharma Science Limited grew +8.2 % a year. The price currently implies +49.5 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Strides Pharma Science Limited (STAR) growing?
The median revenue growth in the sector is +4.3 % a year. That is the yardstick for the growth priced into Strides Pharma Science Limited (+49.5 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Strides Pharma Science Limited (STAR)?
The free-cash-flow yield on the price is 1.11 %: that much free cash flow Strides Pharma Science Limited produces per unit of market value. When it exceeds the discount rate of our models (12.4 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Strides Pharma Science Limited (STAR)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Strides Pharma Science Limited it is ₹912.24 per share (as of Sep 13, 2026), against a price of ₹1,183. It is the blended result of 26 valuation models (cash flow, earnings, asset, dividend).
Is Strides Pharma Science Limited stock overvalued or undervalued in 2026?
As of Sep 13, 2026, STAR trades above its calculated fair value: price ₹1,183, fair value ₹912.24, a gap of about −23% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of STAR?
No. The price is what the market pays today (₹1,183); the fair value is what the company's own numbers justify (₹912.24). For Strides Pharma Science Limited the two are ₹271.16 per share apart. That gap is exactly why we show both numbers side by side.
How much is Strides Pharma Science Limited worth?
The market values Strides Pharma Science Limited at about ₹109B (market capitalisation, as of Sep 13, 2026). Per share that is ₹1,183; our models calculate a fair value of ₹912.24 per share.
What do the bullish and bearish scenarios say about STAR?
Our models span a range for Strides Pharma Science Limited: cautious scenario ₹427.61, base ₹912.24, optimistic ₹1,499 per share (as of Sep 13, 2026, price ₹1,183). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of STAR?
Strides Pharma Science Limited trades at a price-to-earnings ratio of 19.6 (as of Sep 13, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ₹912.24 is built from several models across several years. Other multiples: P/B 3.3, P/S 2.1, EV/EBITDA 11.6.
How solid is the balance sheet of Strides Pharma Science Limited (STAR)?
Balance-sheet figures for Strides Pharma Science Limited (as of Sep 13, 2026): return on equity 20.0%, debt of 0.18 per unit of equity. They feed the Quality Score of 56/100, which measures business quality independently of the share price.
How far is STAR from its 52-week high?
Strides Pharma Science Limited trades at ₹1,183, about 4% below its 52-week high of ₹1,231 and 54% above the low of ₹768.65 (as of Sep 13, 2026). Distance from the high says nothing about value: that is what the fair value of ₹912.24 is for.
Which stocks are comparable to Strides Pharma Science Limited?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Jiangsu Hengrui Pharmaceuticals Co, Sun Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Strides Pharma Science Limited stock attractive at the current price?
The data as of Sep 13, 2026: price ₹1,183, calculated fair value ₹912.24 (−23%), Quality Score 56/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of STAR calculated?
We run Strides Pharma Science Limited through 26 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of ₹912.24, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 15.8 % above its aggregate fair value. Strides Pharma Science Limited itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What should I pay attention to with Strides Pharma Science Limited right now?
The model range is unusually wide (₹427.61 to ₹1,499). The outcome hinges heavily on assumptions, so read the point estimate with caution. Solid but not exceptional quality (56/100) and above fair value, neither a clear bargain nor a standout compounder.
Where does the earnings growth of Strides Pharma Science Limited (STAR) come from?
Earnings per share at Strides Pharma Science Limited grew +16.6 % a year from 2015 to 2026. Broken into its drivers: revenue per share +5.9 %, EBIT margin +0.5 %, tax rate +5.2 %, residual (interest, one-offs) +4.2 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of Strides Pharma Science Limited
How large is the market capitalisation of Strides Pharma Science Limited (STAR)?
The market capitalisation of Strides Pharma Science Limited is ₹109B (≈ $1.1B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Strides Pharma Science Limited (STAR)?
The price-to-sales ratio of Strides Pharma Science Limited is 2.24 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Strides Pharma Science Limited (STAR)?
Earnings per share at Strides Pharma Science Limited are ₹60.39 (price ÷ EPS = P/E 19.6). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Strides Pharma Science Limited (STAR)?
The dividend yield of Strides Pharma Science Limited is 0.4% (payout 8.3%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Strides Pharma Science Limited (STAR)?
The net margin of Strides Pharma Science Limited is 11.4% (fiscal year 2026). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Strides Pharma Science Limited (STAR)?
The return on equity (ROE) of Strides Pharma Science Limited is 20.0% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Strides Pharma Science Limited (STAR)?
On an EBIT basis the return on assets of Strides Pharma Science Limited is 4.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Strides Pharma Science Limited (STAR)?
The operating margin of Strides Pharma Science Limited is 14.1% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Strides Pharma Science Limited (STAR)?
Revenue at Strides Pharma Science Limited is growing +11.2% versus a year earlier (3y avg +9.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Strides Pharma Science Limited (STAR)?
Earnings per share at Strides Pharma Science Limited are growing +54.4% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Strides Pharma Science Limited (STAR) carry?
The net debt of Strides Pharma Science Limited is ₹15.4B (fiscal year 2026, ≈ 12.7 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Strides Pharma Science Limited in the live analysis
One click puts Strides Pharma Science Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
